HighTower Advisors
RVNC

HighTower Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

HighTower Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-30,000
Closed -$46 – 4083
2023
Q4 		$46 Buy
30,000
+29,700
+9,900% +$243K ﹤0.01% 3622
2023
Q3 		$1.04K Buy
+300
New +$5.77K ﹤0.01% 3484

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

HighTower Advisors's RVNC Position: Q4 2024 in Review

HighTower Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 147,400 shares — an estimated $765K sold.

HighTower Advisors first reported a position in RVNC in Q4 2017 and held it in 28 quarters. The position peaked at $24M in Q1 2022. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • HighTower Advisors reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • HighTower Advisors sold 147,400 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $765K.
  • HighTower Advisors first reported a position in Revance Therapeutics, Inc. in Q4 2017 and held it in 28 quarters.
  • HighTower Advisors's Revance Therapeutics, Inc. position peaked at $24M in Q1 2022.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on HighTower Advisors's 13F filing for Q4 2024, filed 7 Feb 2025.